Efficacy and safety of the 12-week sofosbuvir-coblopasvir regimen in treatment of chronic hepatitis C
10.3969/j.issn.1001-5256.2023.03.009
- VernacularTitle:12周索磷布韦联合可洛派韦治疗慢性丙型肝炎的效果和安全性分析
- Author:
Wei ZHANG
1
;
Song ZHAI
2
;
Hong DU
3
;
Fuchun JING
4
;
Limei WANG
5
;
Ye ZHANG
3
;
Bibo KANG
3
;
Jiuping WANG
1
;
Shuangsuo DANG
2
;
Jianqi LIAN
3
;
Hong JIANG
3
Author Information
1. Department of Infectious Diseases, The First Affiliated Hospital of Air Force Medical University, Xi'an 710032, China
2. Department of Infectious Diseases, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710004, China
3. Department of Infectious Diseases, Baoji People's Hospital, Baoji, Shaanxi 721006, China
4. Department of Infectious Diseases, The Second Affiliated Hospital of Air Force Medical University, Xi'an 710038, China
5. Department of Microbiology and Pathogenic Biology, School of Basic Medical Sciences, Air Force Medical University, Xi'an 710032, China
- Publication Type:Original Article_Viral Hepatitis
- Keywords:
Hepatitis C, Chronic;
Coblopasvir;
Sofosbuvir;
Treatment Outcome
- From:
Journal of Clinical Hepatology
2023;39(3):539-545
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the efficacy and safety of the 12-week regimen with sofosbuvir and coblopasvir hydrochloride in the treatment of chronic hepatitis C (CHC) in northwest China. Methods This study enrolled 101 patients with CHC of any genotype who received sofosbuvir (400 mg) combined with coblopasvir hydrochloride (60 mg) for 12 weeks in The First Affiliated Hospital of Air Force Medical University, The Second Affiliated Hospital of Air Force Medical University, The Second Affiliated Hospital of Xi'an Jiaotong University, and Baoji Central Hospital from July 1 to December 31, 2021, among whom 13 had liver cirrhosis and 88 did not have live cirrhosis. Other antiviral drugs such as ribavirin were not added regardless of the presence or absence of liver cirrhosis or the genotype of CHC. Related clinical data ere extracted, including HCV RNA quantification and liver biochemical parameters at baseline, at week 12 of treatment, and at 12 weeks after drug withdrawal. The primary endpoints were sustained virologic response at 12 weeks after the end of treatment (SVR12) and safety at week 12 of treatment, and the secondary endpoint was the effect of the 12-week treatment on liver biochemical parameters. The non-normally distributed continuous data were expressed as M ( P 25 - P 75 ), and the Mann-Whitney U test was used for comparison between groups. Results A total of 101 patients were included in the analysis, among whom there were 55 male patients (54.5%) and 46 female patients, and the median age was 53 years. Among these patients, 12.8% had liver cirrhosis, 1.0% had liver cancer, 3.0% were treatment-experienced patients, and 3.0% had type 2 diabetes. As for genotype distribution, 8% had CHC genotype 1, 60% had CHC genotype 2, 19% had CHC genotype 3, and 6% had CHC genotype 6, and genotype was not tested for 7% of the patients. After 12 weeks of treatment, all 101 patients had a HCV RNA level of below the lower limit of detection and an SVR12 rate of 100%, with a significant reduction in the serum level of alanine aminotransferase (ALT) from baseline to week 12 of treatment ( P < 0.05). Among these patients, 22.7% had concomitant medications such as atorvastatin calcium, aspirin, metformin, nifedipine, bicyclol, and compound glycyrrhizin. The incidence rate of adverse events was 16.8%, and fatigue (12.9%) was the most common adverse event. Conclusion The 12-week treatment with sofosbuvir and coblopasvir hydrochloride can obtain high SVR12 in CHC patients in northwest China and has good antiviral safety, with a significant improvement in abnormal serum ALT at week 12 of treatment.
